TICKERNERD
Menu
ASBPASBPHealthcare · Biotechnology

ASBP Stock Forecast: Aspire Biopharma Holdings, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$7.85

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 14 Aug 2026 — in the weakest quartile.

Market cap
$10.2M
Ticker Nerd rank
15 / 100
Median analyst target
—
Analysts covering
—
Ticker Nerd rank

ASBP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aspire Biopharma Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Aug 2026
15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
92
Growth
73
Issuance
54
Accruals
37
Revisions
25
Volatility
15
Quality
5
Value
3
Momentum
2

Size (92): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ASBP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ASBP, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ASBP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ASBP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Aspire Biopharma Holdings, Inc. (ASBP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
104.1×

Cheaper than 4% of US stocks

Price / book
0.3×

Cheaper than 87% of US stocks

EV / EBITDA
0.1×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
565.4%

Higher than 98% of US stocks

Earnings growth (YoY)
—
Gross margin
20.3%

Higher than 22% of US stocks

Operating margin
−3880.6%

Higher than 3% of US stocks

Net margin
−1.9%

Higher than 28% of US stocks

Returns & dividend
Return on equity
−1032.1%

Higher than 1% of US stocks

Return on assets
60.6%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ASBP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ASBPAspire Biopharma Holdings, Inc.$10.2M
15
LNAILunai Bioworks, Inc.$10.1M
31
TOVXTheriva Biologics, Inc.$10.5M
29
LSTALisata Therapeutics, Inc.$9.8M
56
MTVAMetaVia, Inc.$9.8M
18
BIVIBioVie, Inc.$10.6M
21
INABIN8bio, Inc.$10.7M
45

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aspire Biopharma Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ASBP news & analysis

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

Accesswire · 13 Aug 2026positive

Aspire Biopharma Holdings, Inc. announced that management will present and host one-on-one meetings with investors at Sidoti & Company's Micro-Cap Virtual Investor Conference on August 19-20, 2026. Management plans to discuss its clinical and commercial development pipeline and its recently closed acquisition of Dura Driver Control Systems.

Why it matters — ASBP watchers may gain insight into the company's pipeline and its recently closed automotive acquisition through direct engagement with management at the investor conference.

Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

Accesswire · 10 Aug 2026positive

Aspire Biopharma Holdings announced it has completed its previously announced acquisition of Dura Driver Control Systems, a tier-one automotive supplier with more than 100 years of history and over $200 million in 2025 revenue. The company expects the acquisition to add a new portfolio of products in vehicle and mobility control systems and improve its path to profitability.

Why it matters — This acquisition shifts Aspire into a diversified, higher-revenue enterprise by adding an established global automotive brand with scale, potentially changing the company's revenue profile and path to profitability.

FAQ

Frequently asked questions about ASBP stock

How does Ticker Nerd's model rank ASBP?

As at 14 Aug 2026, Aspire Biopharma Holdings, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

What is the ASBP stock forecast for 2030?

No analyst covering Aspire Biopharma Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASBP are extrapolating price history, which says nothing about the business.

What does Aspire Biopharma Holdings, Inc. do?

Aspire Biopharma Holdings Inc. is an early-stage biopharmaceutical company focused on developing and marketing disruptive sublingual delivery technology for drugs and supplements.

What is the latest news on ASBP?

The most recent item we track (Accesswire, 13 Aug 2026): "Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th". Aspire Biopharma Holdings, Inc. announced that management will present and host one-on-one meetings with investors at Sidoti & Company's Micro-Cap Virtual Investor Conference on August 19-20, 2026. Management plans to discuss its clinical and commercial development pipeline and its recently closed acquisition of Dura Driver Control Systems.

Company

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings Inc. is an early-stage biopharmaceutical company focused on developing and marketing disruptive sublingual delivery technology for drugs and supplements. This patent-pending platform enables rapid absorption directly into the bloodstream through tissues under the tongue, bypassing the gastrointestinal tract to enhance bioavailability, speed of onset, and reduce side effects like gastrointestinal irritation. The company's lead product, Instaprin, is a soluble, pH-neutral, fast-acting sublingual aspirin powder designed for cardiology emergencies and pain management. Aspire Biopharma Holdings Inc. applies its technology across a pipeline of reformulated pharmaceuticals, including melatonin sleep aids, vitamins D, E, and K, testosterone, semaglutide, anti-nausea, anti-psychotic, erectile dysfunction, seizure medications, and others. In the consumer space, it commercializes BUZZ BOMB, a sublingual caffeine supplement in flavors like Tropical Fruit and Mixed Berry, offered through its subsidiary Buzz Bomb Caffeine Company LC for quick energy and cognitive support. Founded in 2021 and headquartered in Estero, Florida, Aspire Biopharma Holdings Inc. operates in the biotechnology sector, targeting improved drug delivery for emergency and everyday health applications.

CEO Mr. Kraig T. Higginson · United States · https://aspirebiolabs.com